Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)
Longeveron (LGVN) recorded quarterly Cash from Financing Activities of $15.5 million in Q1 2026, up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025, and up 26801.72% on a YoY basis from N/an in Q1 2025.
Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $20.2 million (down 29.49% YoY), while the FY2025 annual figure was $4.7 million, down 83.78% from the prior year.
- Cash from Financing Activities was $15.5 million for Q1 2026 at Longeveron, up from $777000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $15.5 million in Q1 2026 to a low of -$193000.0 in Q4 2022.
- Historically, Cash from Financing Activities has averaged $3.2 million across 5 years, with a median of -$27000.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 678.95% in 2022, then soared 27548.0% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$193000.0 in 2022, then soared by 2905.7% to $5.4 million in 2023, then plunged by 100.92% to -$50000.0 in 2024, then surged by 1654.0% to $777000.0 in 2025, then soared by 1893.18% to $15.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $15.5 million (Q1 2026), $777000.0 (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 15.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.49 Mn |
| Mar 31, 2026 | 15.49 Mn |
| Dec 31, 2025 | 777,000.00 |
| Dec 31, 2025 | 777,000.00 |
| Sep 30, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | -133,000.00 |
| Jun 30, 2025 | -133,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Sep 30, 2024 | 13.72 Mn |
| Sep 30, 2024 | 13.72 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Jun 30, 2024 | 15.05 Mn |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | 5.42 Mn |
| Dec 31, 2023 | 5.42 Mn |